From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.
Robert Brooks will outline the clinical progress, commercial potential and global development strategy for Radiance’s lead asset, RB-601 — the first in class bispecific nano ADC engineered to ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced today that it has received clearance from the Center for Drug ...
Robert Brooks will outline the clinical progress, commercial potential and global development strategy for Radiance’s lead asset, RB-601 — the first in class bispecific nano ADC engineered to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results